electroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23
Domestic: | 877-407-4018 |
International: | 201-689-8471 |
Conference ID: | 13699115 |
Webcast: | http://public.viavid.com/index.php?id=138103 |
About electroCore, Inc.
electroCore is a commercial stage bioelectronic medicine company with a proprietary non-invasive vagus nerve stimulation, or nVNS, therapy. nVNS is a platform therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. electroCore’s proprietary gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. gammaCore is CE-marked in the
For more information, visit www.electrocore.com.
Investors:
(+1) 617-535-7743
hans@lifesciadvisors.com
or
Media Contact:
LifeSci Public Relations
(+1) 646-876-4933
sara@lifescipublicrelations.com